## **Uwe Walter**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5401589/publications.pdf Version: 2024-02-01



I WE WAITED

#	Article	IF	CITATIONS
1	Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients. Neurological Sciences, 2022, 43, 2631-2639.	1.9	3
2	Cerebral venous sinus thrombosis after adenovirus-vectored COVID-19 vaccination: review of the neurological-neuroradiological procedure. Neuroradiology, 2022, 64, 865-874.	2.2	8
3	Point-of-Care Ultrasound in Neurology – Report of the EAN SPN/ESNCH/ERcNsono Neuro-POCUS Working Group. Ultraschall in Der Medizin, 2022, 43, 354-366.	1.5	11
4	A red flag for diagnosing brain death: decompressive craniectomy of the posterior fossa. Canadian Journal of Anaesthesia, 2022, 69, 900-906.	1.6	10
5	Sonographic Evaluation of Muscle Echogenicity for the Detection of Intensive Care Unit-Acquired Weakness: A Pilot Single-Center Prospective Cohort Study. Diagnostics, 2022, 12, 1378.	2.6	7
6	Combined assessment by transcranial sonography and Sniffin' Sticks test has a similar diagnostic accuracy compared to brain SPECT for Parkinson's disease diagnosis Clinical Neurology and Neurosurgery, 2022, 220, 107333.	1.4	3
7	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission, 2021, 128, 321-335.	2.8	37
8	From outer space to earth: Ultrasonographic dynamic pupillometry for autonomic testing and neuro-critical care. Ultraschall in Der Medizin, 2021, 42, 7-9.	1.5	0
9	Evaluation of Choroidal Melanoma Vascularization by Color Doppler Flow Imaging: An Option for Follow-Up Tumor Control Assessment after CyberKnife®?. Medicina (Lithuania), 2021, 57, 553.	2.0	2
10	The Role of Ultrasound for the Personalized Botulinum Toxin Treatment of Cervical Dystonia. Toxins, 2021, 13, 365.	3.4	10
11	Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease—An Ultrasound Case-Control Study. Frontiers in Neurology, 2021, 12, 681413.	2.4	12
12	Effects of insular involvement on functional outcome after intracerebral hemorrhage. Acta Neurologica Scandinavica, 2021, 144, 559-565.	2.1	2
13	Adenovirus-Vectored COVID-19 Vaccine–Induced Immune Thrombosis of Carotid Artery. Neurology, 2021, 97, 716-719.	1.1	32
14	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
15	Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. Neurology, 2020, 94, e2109-e2120.	1.1	31
16	How small can small nerves be for diagnostic ultrasonography?. Ultraschall in Der Medizin, 2019, 40, 400-402.	1.5	4
17	Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study. Parkinsonism and Related Disorders, 2019, 68, 40-45.	2.2	13
18	A hexanucleotide repeat modifies expressivity of Xâ€linked dystonia parkinsonism. Annals of Neurology, 2019, 85, 812-822.	5.3	67

#	Article	IF	CITATIONS
19	Differential ageâ€, genderâ€, and sideâ€dependency of vagus, spinal accessory, and phrenic nerve calibers detected with precise ultrasonography measures. Muscle and Nerve, 2019, 59, 486-491.	2.2	31
20	Transcranial brain sonography for Parkinsonian syndromes. Journal of Neurosurgical Sciences, 2019, 63, 441-449.	0.6	2
21	A simplified ultrasonography-guided approach for neurotoxin injection into the obliquus capitis inferior muscle in spasmodic torticollis. Journal of Neural Transmission, 2018, 125, 1037-1042.	2.8	10
22	Age―and sexâ€related heterogeneity in prodromal Parkinson's disease. Movement Disorders, 2018, 33, 1025-1027.	3.9	26
23	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 2018, 265, 856-862.	3.6	51
24	Pregnancy-related knowledge of women with epilepsy — An internet-based survey in German-speaking countries. Epilepsy and Behavior, 2018, 79, 17-22.	1.7	20
25	Atrophy of the Vagus Nerve in Parkinson's Disease Revealed by High-Resolution Ultrasonography. Frontiers in Neurology, 2018, 9, 805.	2.4	55
26	When is "brainstem death―brain death? The case for ancillary testing in primary infratentorial brain lesion. Clinical Neurophysiology, 2018, 129, 2451-2465.	1.5	34
27	Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism. Parkinsonism and Related Disorders, 2017, 37, 43-49.	2.2	12
28	The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study). Journal of Neural Transmission, 2017, 124, 869-879.	2.8	6
29	Transcranial Sonography in Neurodegenerative Diseases with Cognitive Decline. Journal of Alzheimer's Disease, 2017, 61, 29-40.	2.6	7
30	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology, 2017, 264, 112-120.	3.6	32
31	Midbrain raphe hypoechogenicity in migraineurs: An indicator for the use of analgesics but not triptans. Cephalalgia, 2017, 37, 1057-1066.	3.9	10
32	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. Frontiers in Aging Neuroscience, 2016, 8, 121.	3.4	16
33	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Frontiers in Aging Neuroscience, 2016, 8, 147.	3.4	33
34	Transcranial Sonography Findings in Depression in Association With Psychiatric and Neurologic Diseases: A Review. Journal of Neuroimaging, 2016, 26, 257-263.	2.0	30
35	Transcranial Sonography and DaTSCAN in Early Stage Parkinson's Disease and Essential Tremor. European Neurology, 2016, 76, 252-255.	1.4	8
36	Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cellular and Molecular Life Sciences, 2016, 73, 3205-3215.	5.4	37

#	Article	lF	CITATIONS
37	Transcranial Sonography of the Insula: Digitized Image Analysis of Fusion Images with Magnetic Resonance. Ultraschall in Der Medizin, 2016, 37, 604-608.	1.5	13
38	Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location. Movement Disorders, 2016, 31, 302-309.	3.9	19
39	Doppler and Duplex Sonography for the Diagnosis of the Irreversible Cessation of Brain Function ("Brain Deathâ€): Current Guidelines in Germany and Neighboring Countries. Ultraschall in Der Medizin, 2016, 37, 558-578.	1.5	27
40	Accuracy of transcranial brain parenchyma sonography in the diagnosis of dementia with Lewy bodies. European Journal of Neurology, 2016, 23, 1322-1328.	3.3	11
41	The impact of anxiety, seizure severity, executive dysfunction, subjectively perceived psychological deficits, and depression on social function in patients with epilepsy. Epilepsy and Behavior, 2016, 57, 5-8.	1.7	14
42	Case report: absence-status as late reexacerbation of genetic epilepsy of adolescence. Acta Neurologica Belgica, 2016, 116, 675-676.	1.1	3
43	Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 302-310.	1.9	18
44	Anatomic and pathological characterization of choroidal melanoma using multimodal imaging. Melanoma Research, 2015, 25, 252-258.	1.2	17
45	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD. Neuroepidemiology, 2015, 45, 282-297.	2.3	23
46	Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. Journal of Neural Transmission, 2015, 122, 1457-1463.	2.8	45
47	Transcranial sonography of brainstem structures in panic disorder. Psychiatry Research - Neuroimaging, 2015, 234, 137-143.	1.8	16
48	Prediction of Parkinson's disease subsequent to severe depression: a ten-year follow-up study. Journal of Neural Transmission, 2015, 122, 789-797.	2.8	15
49	Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives. Expert Review of Neurotherapeutics, 2014, 14, 923-936.	2.8	52
50	Transcranial Sonography (TCS) of Brain Parenchyma in MovementÂDisorders: Quality Standards, Diagnostic Applications and Novel Technologies. Ultraschall in Der Medizin, 2014, 35, 322-331.	1.5	77
51	Sonography for Diagnosis of Parkinson Disease—From Theory to Practice. Journal of Ultrasound in Medicine, 2014, 33, 2069-2074.	1.7	18
52	Ultrahigh field magnetic resonance and colour Doppler real-time fusion imaging of the orbit – a hybrid tool for assessment of choroidal melanoma. European Radiology, 2014, 24, 1112-1117.	4.5	21
53	Lenticular nucleus hyperechogenicity in Wilson's disease reflects local copper, but not iron accumulation. Journal of Neural Transmission, 2014, 121, 1273-1279.	2.8	24
54	Sonographic detection of basal ganglia abnormalities in spasmodic dysphonia. European Journal of Neurology, 2014, 21, 349-352.	3.3	17

#	Article	IF	CITATIONS
55	Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: A cross-sectional study. Parkinsonism and Related Disorders, 2014, 20, 477-481.	2.2	27
56	Asymmetric Postural Tremor Preceding DOPA-Responsive Parkinsonism – the Transition Disease. Journal of Parkinson's Disease, 2014, 4, 45-55.	2.8	6
57	Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. Journal of Neurology, 2013, 260, 2523-2531.	3.6	16
58	Interhemispheric inhibition in different phenotypes of progressive supranuclear palsy. Journal of Neural Transmission, 2013, 120, 453-461.	2.8	16
59	How to Measure Substantia Nigra Hyperechogenicity in Parkinson Disease. Journal of Ultrasound in Medicine, 2013, 32, 1837-1843.	1.7	25
60	Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson's disease. Journal of Neurology, 2013, 260, 3077-3085.	3.6	27
61	Treatment and course of different subtypes of status epilepticus. Epilepsy Research, 2013, 107, 156-162.	1.6	32
62	Insular stroke is associated with acute sympathetic hyperactivation and immunodepression. European Journal of Neurology, 2013, 20, 153-159.	3.3	85
63	Transcranial sonography in mitochondrial membrane protein-associated neurodegeneration. Parkinsonism and Related Disorders, 2013, 19, 1061-1063.	2.2	7
64	Results of Membrane-activated Chelator Stroke Intervention Randomized Trial of DP-b99 in Acute Ischemic Stroke. Stroke, 2013, 44, 580-584.	2.0	32
65	Xâ€linked Dystoniaâ€Parkinsonism manifesting in a female patient due to atypical turner syndrome. Movement Disorders, 2013, 28, 675-678.	3.9	19
66	Combining Testing Methods. Deutsches Ärzteblatt International, 2013, 110, 345.	0.9	0
67	PET and MRI Reveal Early Evidence of Neurodegeneration in Spinocerebellar Ataxia Type 17. Journal of Nuclear Medicine, 2012, 53, 1074-1080.	5.0	54
68	Sonographic Alteration of Lenticular Nucleus in Focal Task-Specific Dystonia of Musicians. Neurodegenerative Diseases, 2012, 9, 99-103.	1.4	18
69	Transcranial sonography of the cerebral parenchyma: Update on clinically relevant applications. Perspectives in Medicine, 2012, 1, 334-343.	0.3	9
70	Intra- and post-operative monitoring of deep brain implants using transcranial ultrasound. Perspectives in Medicine, 2012, 1, 344-348.	0.3	3
71	Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 441-447.	1.9	81
72	Assessment of Substantia Nigra Echogenicity in German and Filipino Populations Using a Portable Ultrasound System. Journal of Ultrasound in Medicine, 2012, 31, 191-196.	1.7	18

Uwe Walter

#	Article	IF	CITATIONS
73	Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein. Journal of Neural Transmission, 2012, 119, 53-57.	2.8	11
74	Mirror movements in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 393-397.	2.1	27
75	Posterior reversible encephalopathy syndrome (PRES): An unusual primary manifestation of a diffuse large B-cell lymphoma. Clinical Neurology and Neurosurgery, 2011, 113, 819-821.	1.4	11
76	Recurrent aphasic status epilepticus after prolonged generalized tonic–clonic seizures versus a special feature of Todd's paralysis. Epilepsy and Behavior, 2011, 20, 132-137.	1.7	13
77	Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 529-532.	2.0	32
78	Sonographic basal ganglia alterations are related to non-motor symptoms in multiple sclerosis. Journal of Neurology, 2011, 258, 195-202.	3.6	8
79	Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no. Journal of Neural Transmission, 2011, 118, 607-612.	2.8	14
80	Transcranial Sonographic Localization of Deep Brain Stimulation Electrodes Is Safe, Reliable and Predicts Clinical Outcome. Ultrasound in Medicine and Biology, 2011, 37, 1382-1391.	1.5	21
81	Recurrent Stroke after Lobar and Deep Intracerebral Hemorrhage: A Hospital-Based Cohort Study. Cerebrovascular Diseases, 2011, 32, 283-288.	1.7	53
82	Altered callosal function in cerebral microangiopathy. Journal of Neurology, 2010, 257, 590-597.	3.6	6
83	Structural Changes Associated with Progression of Motor Deficits in Spinocerebellar Ataxia 17. Cerebellum, 2010, 9, 210-217.	2.5	33
84	Influence of repetitive transcranial magnetic stimulation on special symptoms in depressed patients. Restorative Neurology and Neuroscience, 2010, 28, 577-586.	0.7	9
85	Method and Validity of Transcranial Sonography in Movement Disorders. International Review of Neurobiology, 2010, 90, 7-34.	2.0	36
86	Transcranial Sonography in Huntington'S Disease. International Review of Neurobiology, 2010, 90, 237-257.	2.0	17
87	Preface. International Review of Neurobiology, 2010, 90, xiii.	2.0	0
88	Transcranial Sonography in Brain Disorders with Trace Metal Accumulation. International Review of Neurobiology, 2010, 90, 166-178.	2.0	27
89	Transcranial sonography findings related to non-motor features of Parkinson's disease. Journal of the Neurological Sciences, 2010, 289, 123-127.	0.6	42
90	Transcranial Sonography-Assisted Stereotaxy and Follow-Up of Deep Brain Implants in Patients with Movement Disorders. International Review of Neurobiology, 2010, 90, 274-285.	2.0	10

#	Article	IF	CITATIONS
91	Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1087-1092.	1.9	81
92	Swallowing Disturbance Pattern Relates to Brain Lesion Location in Acute Stroke Patients. Stroke, 2009, 40, 1903-1906.	2.0	108
93	Deep brain stimulation in dystonia: Sonographic monitoring of electrode placement into the globus pallidus internus. Movement Disorders, 2009, 24, 1538-1541.	3.9	22
94	Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 92-97.	3.2	37
95	Transcranial brain sonography findings in Parkinson's disease: implications for pathogenesis, early diagnosis and therapy. Expert Review of Neurotherapeutics, 2009, 9, 835-846.	2.8	13
96	Transcranial brain sonography findings predict disease progression in multiple sclerosis. Neurology, 2009, 73, 1010-1017.	1.1	57
97	Transcranial sonography findings in weldingâ€related Parkinsonism in comparison to Parkinson's disease. Movement Disorders, 2008, 23, 141-145.	3.9	24
98	Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Movement Disorders, 2008, 23, 596-599.	3.9	59
99	Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology, 2008, 70, 1456-1460.	1.1	132
100	Transcranial sonography in movement disorders. Lancet Neurology, The, 2008, 7, 1044-1055.	10.2	337
101	Contemporary ultrasound systems allow high-resolution transcranial imaging of small echogenic deep intracranial structures similarly as MRI: A phantom study. NeuroImage, 2008, 40, 551-558.	4.2	80
102	Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain, 2007, 130, 1799-1807.	7.6	156
103	Transcranial Brain Sonography Findings in Discriminating Between Parkinsonism and Idiopathic Parkinson Disease. Archives of Neurology, 2007, 64, 1635.	4.5	164
104	Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease. Movement Disorders, 2007, 22, 48-54.	3.9	90
105	Transcranial brain parenchyma sonography in movement disorders: State of the art. Ultrasound in Medicine and Biology, 2007, 33, 15-25.	1.5	234
106	Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Research - Neuroimaging, 2007, 155, 67-73.	1.8	63
107	Predictors of pneumonia in acute stroke patients admitted to a neurological intensive care unit. Journal of Neurology, 2007, 254, 1323-9.	3.6	142
108	Transcranial brain sonography findings related to neuropsychological impairment in multiple sclerosis. Journal of Neurology, 2007, 254, 1149-1152.	3.6	8

#	Article	IF	CITATIONS
109	Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17). Brain, 2006, 129, 2341-2352.	7.6	102
110	Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neuroscience Letters, 2006, 407, 16-19.	2.1	40
111	Overactive bladder in Parkinson's disease: alteration of brainstem raphe detected by transcranial sonography. European Journal of Neurology, 2006, 13, 1291-1297.	3.3	18
112	Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. Journal of Neurology, 2006, 253, 448-454.	3.6	97
113	Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Movement Disorders, 2006, 21, 94-98.	3.9	45
114	Application of Transcranial Sonography in Extrapyramidal Disorders: Updated Recommendations. Ultraschall in Der Medizin, 2006, 27, 12-19.	1.5	48
115	Functional relevance of ceruloplasmin mutations in Parkinson's Disease. FASEB Journal, 2005, 19, 1851-1853.	0.5	77
116	Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet, The, 2005, 366, 1794-1796.	13.7	430
117	Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology, 2005, 64, 1726-1732.	1.1	126
118	Screening for mutations of the IRP2 gene in Parkinson?s disease patients with hyperechogenicity of the substantia nigra. Journal of Neural Transmission, 2004, 111, 515-521.	2.8	24
119	Brain parenchyma sonography detects preclinical parkinsonism. Movement Disorders, 2004, 19, 1445-1449.	3.9	147
120	Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology, 2004, 63, 504-509.	1.1	122
121	Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology, 2003, 60, 74-77.	1.1	240
122	Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neuroscience Letters, 2003, 352, 53-56.	2.1	49
123	Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. Journal of Neural Transmission, 2002, 109, 191-196.	2.8	143
124	Characterization of the interaction of alkaline phosphatase with an activity inhibiting monoclonal antibody by progress curve analysis. Journal of Immunological Methods, 1995, 182, 29-39.	1.4	0
125	Brain parenchyma imaging. , 0, , 288-299.		0
126	Ultrasound Guidance for Botulinum Toxin Application. , 0, , 149-153.		0

Ultrasound Guidance for Botulinum Toxin Application. , 0, , 149-153. 126